Compare BWMN & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMN | PRME |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.6M | 536.4M |
| IPO Year | 2021 | 2022 |
| Metric | BWMN | PRME |
|---|---|---|
| Price | $26.10 | $3.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $45.50 | $7.56 |
| AVG Volume (30 Days) | 129.2K | ★ 4.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 329.41 | 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $490,017,000.00 | $4,632,000.00 |
| Revenue This Year | $14.93 | $7.06 |
| Revenue Next Year | $11.57 | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.88 | ★ 55.28 |
| 52 Week Low | $25.07 | $2.67 |
| 52 Week High | $45.83 | $6.94 |
| Indicator | BWMN | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 31.75 | 42.35 |
| Support Level | $25.52 | $2.68 |
| Resistance Level | $36.86 | $3.68 |
| Average True Range (ATR) | 1.12 | 0.26 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 20.81 | 10.18 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.